A new medication called daraxonrasib has doubled survival times for stage 4 pancreatic cancer patients in clinical trials, offering a significant breakthrough for one of the deadliest forms of the disease. While not a cure, the targeted pill directly addresses the KRAS mutation common to the cancer, prompting a pending FDA review.
Progress in gastrointestinal oncology typically unfolds over years or even decades, making recent clinical trial results for a novel targeted therapy a major milestone for specialists. Dr. Mark Lewis, director of gastrointestinal oncology at Intermountain Health, described the development as a major milestone for pancreatic cancer treatment, noting that it represents a significant advancement in targeting the KRAS mutation.
Clinical Trial Results and the KRAS Mutation Mechanism
Until now, standard management for stage 4 pancreatic cancer relied heavily on intravenous chemotherapy administered every two weeks. In clinical trials, daraxonrasib doubled survival time for stage 4 patients, extending median survival from 6.7 months on traditional chemotherapy to 13.2 months.
The underlying driver of pancreatic cancer is frequently a mutation known as KRAS. Daraxonrasib marks the first treatment to address this specific mutation directly. According to clinical evaluations presented at the American Society of Clinical Oncology conference—where the study received a standing ovation—the medication effectively shuts down the growth signals driven by KRAS, halting both tumor growth and spread.
Dr. Mark Lewis emphasized that while the treatment is not a cure, it offers a potentially better-tolerated and more effective option compared to traditional chemotherapy, with the potential for long-term disease control.
Expanded Access Program and Regulatory Timeline
Although the Food and Drug Administration has not yet granted final approval for daraxonrasib, the manufacturer submitted an application on July 22. Regulatory review typically takes roughly six to eight weeks, meaning the medication could become more widely available soon. In the interim, ten Intermountain Health hospitals—including locations across Utah, Colorado, and Montana—alongside the Huntsman Cancer Institute and Utah Cancer Specialists, are able to provide the drug to eligible individuals through an Expanded Access Program.
Lewis noted that the program functions similarly to an individual trial. Intermountain Health has already approved nine patients who are awaiting their initial shipments directly from the manufacturer. Clinicians emphasize that daraxonrasib serves as a disease-control mechanism rather than a cure, noting that surgery remains the sole curative option, which is rarely feasible for stage 4 patients whose cancer has metastasized or wrapped around vital structures.
Patient Trade-offs and the Reality of Side Effects
While the oral treatment offers a potentially better-tolerated alternative to lifelong intravenous chemotherapy, it comes with notable side effects, most commonly skin rashes, diarrhea, and mouth sores. Former U.S. Senator Ben Sasse of Nebraska has helped bring visibility to these challenges by publicly discussing his experiences with rashes while participating in clinical trials for the drug.
Medical professionals emphasize that patients pursuing this therapy maintain realistic expectations regarding what an additional year of life entails.
Dr. Mark Lewis acknowledged that while the drug is not a cure, it provides a more tolerable and effective long-term treatment option compared to traditional chemotherapy.
With roughly 67,000 Americans diagnosed annually and approximately 52,000 dying from the disease, pancreatic cancer remains the third leading cause of cancer deaths, largely due to the absence of early screening tools. As the FDA considers the pending application for daraxonrasib following its two-year trial phase, the medical community watches to see how quickly precision oncology can expand access for patients facing advanced diagnoses.
